All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-10-18T12:13:41.000Z

After the CARDAMON trial update, what do we know about the role of ASCT and K maintenance in NDMM?

By Erika Roa, Mark Maitland, Addy Dullaghan
Featured
Rakesh Popat
Oct 18, 2021
Share:

Bookmark this article

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK. We asked, After the CARDAMON trial update, what do we know about the role of autologous stem cell transplant and K maintenance in newly diagnosed multiple myeloma?

After the CARDAMON trial update, what do we know about the role of ASCT and K maintenance in NDMM?

Popat discusses the CARDAMON (NCT02315716) phase II clinical trial, investigating carfilzomib maintenance in patients with newly diagnosed multiple myeloma following autologous stem cell transplant.

 

More about...
Auto-HSCTCARDAMONCarfilzomibIMWIMW 2021Newly diagnosed multiple myeloma

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
27 votes - 5 days left ...

Related articles

Add bookmark

Carfilzomib as maintenance therapy after upfront and salvage ASCT

Carfilzomib, a next-generation proteasome inhibitor, has demonstrated encouraging clinical effects in newly diagnosed and relapsed/refractory multiple myeloma (MM) when combined with...

Dec 20, 2021
Add bookmark

Carfilzomib as maintenance therapy after upfront and salvage ASCT

Carfilzomib, a next-generation proteasome inhibitor, has demonstrated encouraging clinical effects in newly diagnosed and...

Dec 20, 2021
Add bookmark

Is there still a role in MM for auto-SCT after induction with a quadruplet combination?

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Luciano J. Costa, University of Alabama at Birmingham,...

Dec 13, 2021
Add bookmark

Is there still a role in MM for auto-SCT after induction with a quadruplet combination?

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Luciano J....

Dec 13, 2021

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox